ATRX:OTC-Adhera Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0002

Change

0.00 (0.00)%

Market Cap

USD 1.44K

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

-0.12 (-0.12%)

USD 36.53B
UCBJF UCB SA

N/A

USD 35.59B
ARGNF argenx SE

N/A

USD 33.74B
GNMSF Genmab A/S

-2.12 (-0.95%)

USD 14.31B
WXIBF WuXi Biologics

N/A

USD 10.26B
IVBIY IVBIY

N/A

USD 9.55B
WXXWY WuXi Biologics (Cayman) Inc

-0.16 (-3.69%)

USD 9.11B
ZLDPF Zealand Pharma A/S

N/A

USD 8.66B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 8.61B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 8.60B

ETFs Containing ATRX

LCPE:LSE Ossiam Shiller Barclays C.. 6.93 % 0.00 %

-320.00 (-1.61%)

USD 0.17B
EL4D:XETRA Deka STOXX® Europe Stron.. 6.03 % 0.00 %

-0.47 (-1.61%)

USD 0.03B
L6EW:LSE Ossiam Stoxx Europe 600 E.. 5.81 % 0.00 %

-70.00 (-1.61%)

USD 0.12B
S6EW:PA Ossiam Stoxx Europe 600 E.. 5.81 % 0.00 %

-1.44 (-1.61%)

USD 0.12B
OSX6:XETRA Ossiam Stoxx Europe 600 E.. 5.81 % 0.00 %

-1.42 (-1.61%)

USD 0.16B
S6EW:SW Ossiam STOXX® Europe 600.. 5.81 % 0.00 %

N/A

USD 0.12B
EXID:XETRA iShares MDAX® UCITS ETF .. 5.33 % 0.00 %

-0.06 (-1.61%)

USD 1.12B
OND ProShares On-Demand ETF 5.29 % 0.00 %

-0.25 (-1.61%)

USD 0.83M
XDGM:F db x-trackers Mittelstand.. 5.24 % 0.00 %

-0.36 (-1.61%)

USD 0.11B
XDGM:XETRA db x-trackers Mittelstand.. 5.24 % 0.00 %

-0.34 (-1.61%)

USD 0.09B
ELF1:XETRA Deka MDAX® UCITS ETF 5.08 % 0.00 %

-4.10 (-1.61%)

USD 0.35B
DEAM:XETRA Invesco MDAX® UCITS ETF .. 5.08 % 0.00 %

-0.72 (-1.61%)

USD 0.24B
EL4E:XETRA Deka STOXX Europe Strong .. 3.07 % 0.00 %

-0.57 (-1.61%)

USD 0.04B
FEUZ:LSE First Trust Eurozone Alph.. 1.13 % 0.00 %

-14.75 (-1.61%)

USD 0.06B
FEUD:LSE First Trust Eurozone Alph.. 1.13 % 0.00 %

-13.75 (-1.61%)

USD 0.02B
FEUZ First Trust Eurozone Alph.. 1.13 % 0.80 %

-0.01 (-1.61%)

USD 0.06B
S6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

-1.45 (-1.61%)

N/A
OSX6:F Ossiam Lux - Ossiam Stoxx.. 0.00 % 0.00 %

-1.46 (-1.61%)

N/A
EXS3:XETRA iShares MDAX® UCITS ETF .. 0.00 % 0.00 %

-3.55 (-1.61%)

USD 1.12B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -86.67% 13% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.67% 13% F 5% F
Trailing 12 Months  
Capital Gain -60.00% 27% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.00% 27% F 16% F
Trailing 5 Years  
Capital Gain -99.78% 10% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.78% 10% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -16.09% 30% F 16% F
Dividend Return -16.09% 30% F 15% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 98.79% 48% F 35% F
Risk Adjusted Return -16.29% 37% F 26% F
Market Capitalization 1.44K 3% F 2% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.